Objective To evaluate the cardiotoxicity of chemotherapy combined with targeted therapy for HER2 positive breast cancer.Metholds Patients were devided into:chemotherapy group(C group;51 cases),chemotherapy plus trastuzumab group(C+H group;62 cases)and chemotherapy plus trastuzumab and pertuzumab group(C+H+P group;47 cases).The changes of heart rate,left ventricular ejection fraction(LVEF)and creatine kinase-MB(CK-MB)at baseline,3,6,9,12 and 24 month after treatment were analyzed,and the Incidence rate of cardiotoxicity was also calculated.Results The LVEF level in C group significantly de-creased at 3 month,6 mouth and 9 mouth(all P＜0.05),the same significant differences were also detected in C+H group and C+H+P group at 3 month,6 month,9 month and 12 month(all P＜0.01).The comparison in groups:For C group,the LVEF level of C+H group and C+H+P group at 3 month and 6 month significantly decreased(all P＜0.01);there were no significant differences in heart rate and CK-MB.The cardiotoxicity was found in 5 patients of C group,20 patients of C+H group and 14 patients of C+H+P group,and there was statistical difference between groups(P＜0.05),and there was no statistical difference between C+H group and C+H+P group(P>0.05).Conclusion Differences of cardiotoxicity between chemotherapy combined with single or double tar-geted therapy were not detected,and most of them can recoverable.The LVEF level may be used as an effective method to predict cardiotoxicity of targeted therapy.
关键词
Her2阳性乳腺癌/曲妥珠单抗/帕妥珠单抗/心脏毒性
Key words
Her2 positive breast cancer/trastuzumab/pertuzumab/cardiotoxicity
维普
万方数据